It has been previously validated as a CMA substrate (Liu et al, 2022), and in accordance, we found that cellular levels of ACSL4 were markedly elevated and lysosomal degradation of ACSL4 was stalled in iPSC-RPE from donors with AMD (Fig. 3E,F). Here, ACSL4 is linked to age-related macular degeneration.